These channels include the hERG K+ channel that is a target for many anti-arrhythmia drugs, as well as the KCNQ K+ channel, and mutations in both of these genes contribute to long QT syndrome (LQTS) which can trigger cardiac arrhythmias and are likely significant contributors to sudden cardiac death. The gene discussed is KCNH2; the disease is cardiac arrhythmia.